Shopping Cart
Remove All
Your shopping cart is currently empty
Tigatuzumab (Alias: TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody)
Catalog No. T76793 Copy Product Info
🥰Excellent
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
Tigatuzumab
Copy Product Info🥰Excellent
Catalog No. T76793
Alias TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
Tigatuzumab
Cas No. 918127-53-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $589 | In Stock | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.9% (SDS-PAGE); 96.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer. |
| Targets&IC50 | MIAPaCa2 cells:2.95 μg/mL |
| In vitro | Tigatuzumab showed sensitivity to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 μg/mL and 8.21 μg/mL, respectively.[1] Tigatuzumab (3-8 μg/mL; 5 hours) was able to induce apoptosis in cancer cells. [1] |
| In vivo | Tigatuzumab (3 mg/kg; i.v.; once weekly for 4 weeks) was effective in inhibiting tumor growth of human pancreatic cancer MIA PaCa-2-RFP in a xenograft mouse model. [1] |
| Synonyms | TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF10B/TRAILR2/CD262 |
| Molecular Weight | 144.63 kDa |
| Cas No. | 918127-53-4 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Tigatuzumab | purchase Tigatuzumab | Tigatuzumab cost | order Tigatuzumab | Tigatuzumab in vivo | Tigatuzumab in vitro | Tigatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.